734-936-8000 - Service Desk | Request Support

Psychiatric Pharmacogenomics: A Practical Guide to Gene-Drug Interactions and Tests

To begin this activity, click Enroll. Once logged in, learners can access educational content, assessments, and evaluations. Learners who successfully complete the activity will be able to print a certificate.

Step Status
Educational Materials
Evaluation
Release Date: Mon, 4/20/20
Termination Date: Thu, 12/31/20
Credits: 5
Description: To Claim
• Click ENROLL
• Click link to view Educational Materials
• Return to MiCME to complete course survey and evaluation
• Complete evaluation in MiCME, confirm the number of credits, attest and submit
Educational Objectives: At the end of this activity, each participant should be able to:
  1. Describe basic pharmacogenomics concepts.
  2. Distinguish which gene-drug relationships have the most evidence supporting their implementation in the clinic.
  3. Identify which psychiatric pharmacogenomics tests to order.
  4. Confidently formulate medication treatment plans using pharmacogenomics test results.
Target Audience: This activity is appropriate for House Officers, Nurse Practitioners, Other Healthcare Professionals, Physician Assistants, Physicians in the fields of Family Medicine, General Medicine, Internal Medicine, Neurology, Other Healthcare Professions, Pediatrics, Primary Care, Psychiatry.
Accreditation Information: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Michigan Medical School and University of Michigan College of Pharmacy. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The University of Michigan Medical School designates this enduring material activity for a maximum of 5.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Original Release Date: April 2020
Termination Date: March 2023
Additional Info: Presenter:
Amy Pasternak, PharmD, BCPS
Kyle Burghardt, PharmD
Kristen Ward, PharmD

Educational Planner
Sagar Parikh, MD

Educational Co-Planner
Kristen Ward, PharmD
Amy Pasternak, PharmD
Danielle Taubman, MPH

Moderator:
Sagar Parikh, MD

*Financial Disclosures:
Sagar Parikh, MD
Consultant/Advisory Role: AssureRx Health Mason, Ohio

There are no other relevant financial relationships to disclose for this CME activity.

References:
  1. Bradley et al. Journal of Psychiatric Research. 2018;96:100-107
  2. Clinical Pharmacogenetics Implementation Consortium (CPIC): cpicpgx.org
  3. FDA Pharmacogenomic Biomarkers Table: Table of Pharmacogenomic Biomarkers in Drug Labeling
  4. GeneSight Psychotropic: Genesight
  5. Greden, J. F. et al. J. Psychiatr. Res. 111, 59–67 (2019).
  6. NIH Genetic Testing Registry: NCBI Resources
  7. Pharmacogenomics KnowledgeBase (PharmGKB): PharmGKB
  8. Public Database of Clinical Laboratory Improvement Amendments (CLIA) Tests: CLIA - Clinical Laboratory Improvement Amendments

Credits available:

AMA PRA Category 1: 5.00
Participation: 5.00